Iovance Biotherapeutics announced release of an abstract that will be presented at ESMO demonstrating the ability to produce TIL from lymphoma
"As we explore potential utilization of TIL in treatment of multiple cancer types, we present data at ESMO that demonstrate the ability to produce TIL from lymphoma that have similar functionality as TIL generated from melanoma, giving us reason to further explore the potential of our TIL cell therapy for lymphoma patients in the future," said Dr. Maria Fardis, PhD, MBA, Chief Executive Officer of Iovance Biotherapeutics. "Leveraging our experience in TIL generation from solid tumors to blood-born cancers is a natural extension of our learnings to date. We are exploring potential collaborations with lymphoma experts to supplement our research efforts. The data to be presented at ESMO is indicative of our efforts in becoming a leader in TIL treatment for a variety of tumor types."
Iovance Biotherapeutics also announced that the FDA has granted Fast Track designation for LN-144, the Company's adoptive cell therapy using its TIL technology, for the treatment of advanced melanoma
C-144-01 is a Phase 2 study evaluating LN-144, Iovance's lead product, for treatment of patients with metastatic melanoma. The study is currently enrolling and is expected to enroll up to 60 patients in two cohorts: Cohort 1 allows for non-cryopreserved TIL product to be administered to patients, while Cohort 2 involves administration of a cryopreserved product.
Description
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Address
999 Skyway Rd Ste 150
SAN CARLOS, CA 94070-2724
United States
SAN CARLOS, CA 94070-2724
United States
Website
http://www.iovance.com/Key stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -63.92% | -38.12% |
| Return on average equity | -67.21% | -75.55% |
| Employees | 51 |
No comments:
Post a Comment